Cogent Biosciences, Inc.(COGT)Earnings, Financials & Key RatiosCogent Biosciences, Inc. (COGT) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the current ratio of 15.14 provides a substantial liquidity buffer for near-term clinical trials, the lack of commercial revenue and the $87.3 million quarterly free cash flow burn warrant extreme caution regarding long-term capital sustainability.
Cogent Biosciences, Inc. (COGT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Cogent Biosciences, Inc. (COGT) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.53vs $0.53+0.0% | —vs $500 |
| Q1 2026 | Feb 17, 2026 | $0.55vs $0.51-7.8% | —vs $2M |
| Q4 2025 | Nov 7, 2025 | $0.50vs $0.54+7.4% | — |
| Q3 2025 | Aug 5, 2025 | $0.53vs $0.55+3.6% | — |
Recent stock market news and headlines for Cogent Biosciences, Inc. (COGT)
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for AdvSM patients
Key metrics vs top competitors for Cogent Biosciences, Inc. (COGT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $40.01 | $6.84B | -15.69 | — | — | -73.7% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $90.00 | $6.83B | -26.87 | -12.38% | -654.43% | -50.62% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $6.09 | $37.69M | -2.49 | -44.59% | -1919.68% | -139.47% | — |
Cogent Biosciences, Inc. (COGT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Cogent Biosciences, Inc. (COGT) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Feb 17, 2026·SEC
Dec 8, 2025·SEC
Get notified when COGT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cogent Biosciences, Inc. (COGT) stock FAQ — growth, dividends, profitability & financials explained
Cogent Biosciences, Inc. (COGT) reported a net loss of $354.3M for fiscal year 2025.
Cogent Biosciences, Inc. (COGT) has a return on equity (ROE) of -73.7%. Negative ROE indicates the company is unprofitable.
Cogent Biosciences, Inc. (COGT) had negative free cash flow of $286.3M in fiscal year 2025, likely due to heavy capital investments.
